A new era in tackling brain diseases

Nanocarry is developing a new class of brain therapeutics, which combines biological approaches with nanoparticles to allow biologics to cross the Blood Brain Barrier, creating first-in-class therapeutics for neuro-oncology indications and CNS diseases.

Nanocarry’s Team & Story

Powered by the convergence of multidisciplinary expertise
Nanocarry is developing an innovative delivery technology platform pioneered over the past decade in the Nano-Bioengineering lab of Prof. Rachela Popovtzer at Bar Ilan University, Israel. With pre-seed financing from NfX and TechBio, Nanocarry’s nano-chemistry and biology labs are working synergistically to develop first-in-class product candidates, while scaling and optimizing the manufacturing process of its bioengineered gold nanoparticles.

Meet Nanocarry’s Multidisciplinary Team

revital3

Revital Mandil Levin

CEO & Co-founder
oshra

Oshra Betzer

COO & Co-founder
Rachela Background

Rachela Popovtzer

CSO & Co-founder
Michal

Michal Roytman

CBO
Ayelet

Ayelet Zafran

VP R&D
Kostia Background

Konstantin Rozenberg

Senior Scientist
sivan background final

Sivan Shahar

Research Scientist
Barel background

Barel Ohanuna

Research Scientist
ella background

Ella Abramovich

Research Assistant
background7

Aaron Zucker

Board Member, Sapir Venture Partners
omri

Omri Amirav-Drory

Board Member, NFX

Meet Nanocarry’s Advisory Team

background1

Shani Paluch-Shimon, MD

Director of Breast Oncology, Hadassah Medical Center
background5

Iris Alroy

Co-Founder and CSO, Anima Biotech, Expert in Preclinical Development
background6

Ofra Levy Hacham

VP RA/Clinical, Solgel Technologies, Expert in CMC and Regulation
Skip to content